Hokuriku Pharmaceutical announced that the company recently received the “Drug Registration Certificate” for paroxetine hydrochloride enteric sustained-release tablets approved and issued by the State Drug Administration. “Paroxetine hydrochloride enteric sustained-release tablets” have been approved according to the 4 types of chemicals. It is considered that they have passed the consistent evaluation of the quality and efficacy of generic drugs. It will further enrich the company's neuropsychiatric product line and help enhance the market competitiveness of the company's products.
北陆药业：获得盐酸帕罗西汀肠溶缓释片《药品注册证书》
Hokuriku Pharmaceutical: Obtained “Drug Registration Certificate” for paroxetine hydrochloride enteric sustained-release tablets
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.